<DOC>
	<DOCNO>NCT01978327</DOCNO>
	<brief_summary>GSK2647544 orally available , selective inhibitor Lp PLA2 develop treatment Alzheimer 's disease . The current study single-blind , randomise , placebo-controlled , 4-cohort study ass safety , tolerability , pharmacokinetics pharmacodynamics repeat dos GSK2647544 . Cohorts 1 , 2 3 evaluate escalating dos GSK2647544 young healthy volunteer 7 day , 7 day , 14 day , respectively . Cohort 4 evaluate repeat dos GSK2647544 healthy elderly volunteer 14 day . Additionally , Cohorts 1 3 include assessment potential drug-drug interaction simvastatin examine CYP3A4 inhibition GSK2647544 .</brief_summary>
	<brief_title>GSK2647544 RD , DDI Healthy Young Elderly Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>Males females 18 64 year age inclusive , defined young subject study , eligible Cohorts 13 Males female â‰¥65 year age , define elderly subject study , eligible Cohort 4 Healthy determine responsible experienced physician A female subject eligible participate nonchildbearing potential Male subject female partner childbearing potential must agree use one contraception method Body weight &gt; 50 kg ( 110 pound ) body mass index ( BMI ) 19 32 Aspartate aminotransferase ( AST ) , Alanine transaminase ( ALT ) , alkaline phosphatase bilirubin &lt; = 1.5xUpper Limit Normal ( ULN ) Average triplicate QTcB value average triplicate QTcF value must &lt; 450 msec Capable give write informed consent Subjects LpPLA2 activity &lt; =20 nanomole/minute/milliliter ( mL ) ( subject 2 known birth parent least 50 % Japanese , Chinese , Korean ancestry ) History asthma , anaphylaxis anaphalactoid reaction , severe allergic response History hypercoagulable state history thrombosis History biliary tract disease include history liver disease elevate liver function test know unknown etiology Positive Human immunodeficiency virus ( HIV ) , Hepatitis B Hepatitis C screen History regular use tobacco nicotinecontaining product within 6 month study Unable abstain alcohol caffeine xanthinecontaining product 24 h prior start dose Unable refrain use prescription nonprescription drug vitamin within 7 day 5 halflives ( whichever longer ) prior administration study Urinary cotinine level indicative smoke history regular use tobacco nicotinecontaining product within 6 month prior screen ( Note : This apply healthy young subject screen Cohorts 13 . Healthy elderly subject cohort 4 social smoker must give smoking period unit ) positive prestudy drug/alcohol screen Unable refrain consumption Seville orange , grapefruit grapefruit juice within 7 day prior first dose study medication followup visit Subjects take statin , medicine contraindication statin , know potent inhibitiors inducer CYP3A4 4 week 5 halflives ( whichever longer ) prior screen able discontinue use throughout participation clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Alzheimer 's disease</keyword>
	<keyword>GSK2647544</keyword>
	<keyword>drug-drug interaction</keyword>
	<keyword>healthy subject</keyword>
	<keyword>Lp-PLA2</keyword>
	<keyword>simvastatin</keyword>
</DOC>